Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01532817 · ClinicalTrials.gov registry record · NA
Relief of Acute Bronchoconstriction/Asthma Using the Non-Invasive AlphaCore Device
A NA study, sponsored by ElectroCore.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT01532817: Completed NA study, sponsored by ElectroCore.
NCT01532817 is a NA study that has completed, run by ElectroCore. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01532817, a NA study, has completed, sponsored by ElectroCore.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this pilot study is to collect preliminary clinical data related to the safety and preliminary clinical benefits of non-invasive vagal nerve stimulation with the AlphaCore™ device for the relief of acute bronchoconstriction due to asthma. Up to 30 subjects who meet all inclusion/exclusion criteria and consent to participate in the study may be enrolled at up to 5 investigational (study) sites. The study sites are clinic settings capable of treating any potential complications of bronchoconstriction, an acute exacerbation of asthma, and any emergencies associated with use of the investigational device.
Primary Outcome
Safety- number of participants with adverse events, including device-related, serious or unanticipated
Interventions
- DEVICE AlphaCore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-05 |
| Phase | NA |
What the finished NCT01532817 record still lists
NCT01532817 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which AlphaCore is the first listed.
NCT01532817 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01532817 about?
NCT01532817 is a clinical study titled "Relief of Acute Bronchoconstriction/Asthma Using the Non-Invasive AlphaCore Device". The purpose of this pilot study is to collect preliminary clinical data related to the safety and preliminary clinical benefits of non-invasive vagal nerve stimulation with the AlphaCore™ device for the relief of acute bronchoconstriction due to asthma. Up to 30 subjects who meet all inclusion/excl...
What is the current status of trial NCT01532817?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2012-01. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01532817?
The interventions under investigation include: AlphaCore (DEVICE).
Who is sponsoring clinical trial NCT01532817?
This trial is sponsored by ElectroCore, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01532817's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia